Hospira Likely Will Revisit 2004 Guidance At End Of Summer Season
This article was originally published in The Gray Sheet
Executive Summary
Hospira is maintaining its "conservative" top-line guidance for the 2004 second half - at least in the eyes of some Wall Street onlookers - due to an expected slowdown in hospital product sales this summer
You may also be interested in...
Hospira Assumes Responsibility For Recent Abbott Warning Letter
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.